Toxicity of HPA-23 (ammonmm-21-tungsto-9-antimoniate) for normal human myeloid progenitor cells (GM-CFU) in vitro

Aymard, J.P.; Ferry, Robert J.; Janot, C.; Schooneman, F.; Lfgras, B.; T, May; Streiff, F

doi:10.1016/0753-3322(89)90245-x

Cited by 3 publications

(2 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, it may be pertinent to consider each POM carefully when designing POM-drug composites for anti-cancer therapy. Purely inorganic POMs have been reported to enhance cellular reactive oxygen species to have anti-cancer effects [ 27 ]; however, clinical and pre-clinical toxicities have been reported that must be taken into consideration when evaluating their utility in cancer therapy [ 28 , 29 ]. Malignant brain tumors have been reported to have altered antioxidant capacity and increased oxidative stress compared to normal brain tissue.…”

Section: Discussionmentioning

confidence: 99%

Polyoxometalate Nanoparticles as a Potential Glioblastoma Therapeutic via Lipid-Mediated Cell Death

Petronek

Allen²,

Luthe³

et al. 2022

IJMS

View full text Add to dashboard Cite

Polyoxometalate nanoparticles (POMs) are a class of compounds made up of multiple transition metals linked together using oxygen atoms. POMs commonly include group 6 transition metals, with two of the most common forms using molybdenum and tungsten. POMs are suggested to exhibit antimicrobial effects. In this study, we developed two POM preparations to study anti-cancer activity. We found that Mo-POM (NH4)Mo7O24) and W-POM (H3PW12O40) have anti-cancer effects on glioblastoma cells. Both POMs induced morphological changes marked by membrane swelling and the presence of multinucleated cells that may indicate apoptosis induction along with impaired cell division. We also observed significant increases in lipid oxidation events, suggesting that POMs are redox-active and can catalyze detrimental oxidation events in glioblastoma cells. Here, we present preliminary indications that molybdenum polyoxometalate nanoparticles may act like ferrous iron to catalyze the oxidation of phospholipids. These preliminary results suggest that Mo-POMs (NH4)Mo7O24) and W-POMs (H3PW12O40) may warrant further investigation into their utility as adjunct cancer therapies.

show abstract

Section: Discussionmentioning

confidence: 99%

Polyoxometalate Nanoparticles as a Potential Glioblastoma Therapeutic via Lipid-Mediated Cell Death

Petronek

Allen²,

Luthe³

et al. 2022

IJMS

View full text Add to dashboard Cite

show abstract

“…The POM known as ammonium-21-tungsto-9-antimoniate (HPA-23) ended with an HIV/AIDS clinical trial in the 1980s. This compound failed due to unacceptable adverse effects and minor benefits [ 16 , 17 , 18 ]. Since then, several groups have synthesized and identified a number of new generations of POMs with improved potency and reduced toxicity [ 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 ], although the mechanisms remain unclear.…”

Section: Introductionmentioning

confidence: 99%

Inhibition of Human Immunodeficiency Virus Type 1 Entry by a Keggin Polyoxometalate

Wang

Zhang

et al. 2018

Viruses

View full text Add to dashboard Cite

Here, we report the anti-human immunodeficiency virus (HIV) potency and underlying mechanisms of a Keggin polyoxometalate (PT-1, K6HPTi2W10O40). Our findings showed that PT-1 exhibited highly potent effects against a diverse group of HIV type 1 (HIV-1) strains and displayed low cytotoxicity and genotoxicity. The time-addition assay revealed that PT-1 acted at an early stage of infection, and these findings were supported by the observation that PT-1 had more potency against Env-pseudotyped virus than vesicular stomatitis virus glycoprotein (VSVG) pseudotyped virus. Surface plasmon resonance binding assays and flow cytometry analysis showed that PT-1 blocked the gp120 binding site in the CD4 receptor. Moreover, PT-1 bound directly to gp41 NHR (N36 peptide), thereby interrupting the core bundle formation of gp41. In conclusion, our data suggested that PT-1 may be developed as a new anti-HIV-1 agent through its effects on entry inhibition.

show abstract

Synthesis and evaluation of pyridinium polyoxometalates as anti-HIV-1 agents

Wang

Sun

et al. 2017

Bioorganic & Medicinal Chemistry Letters

View full text Add to dashboard Cite

Toxicity of HPA-23 (ammonmm-21-tungsto-9-antimoniate) for normal human myeloid progenitor cells (GM-CFU) in vitro

Cited by 3 publications

References 9 publications

Polyoxometalate Nanoparticles as a Potential Glioblastoma Therapeutic via Lipid-Mediated Cell Death

Polyoxometalate Nanoparticles as a Potential Glioblastoma Therapeutic via Lipid-Mediated Cell Death

Inhibition of Human Immunodeficiency Virus Type 1 Entry by a Keggin Polyoxometalate

Synthesis and evaluation of pyridinium polyoxometalates as anti-HIV-1 agents

Contact Info

Product

Resources

About